Glaucoma

Further Resources: Ophthalmology · Optometry

Editor's Choice

Ocular perfusion pressure is a glaucoma risk, according to growing evidence

Recent literature has identified ocular perfusion pressure as a glaucoma risk factor. Ophthalmologists need to be aware of the growing evidence supporting this theory, according to one expert.

LATEST ARTICLES

Endocyclophotocoagulation beneficial for those with glaucoma undergoing cataract surgery

Endocyclophotocoagulation (ECP) can be performed easily in patients with medically controlled glaucoma who are undergoing cataract surgery, to provide additional IOP lowering and reduce medication use. Misunderstanding that ECP is a completely different procedure than transscleral cyclodestruction contributes to under-use of this very safe procedure, according to one ophthalmologist.

Retinal photographs facilitate glaucoma diagnosis with new software

New software (MatchedFlicker, EyeIC) uses time series retinal photographs to convert change into motion and could improve the accuracy and speed of detecting glaucomatous progression.

Ocular perfusion pressure is a glaucoma risk, according to growing evidence

Recent literature has identified ocular perfusion pressure as a glaucoma risk factor. Ophthalmologists need to be aware of the growing evidence supporting this theory, according to one expert.

Glaucoma: Hyperemia a common cause for medication changes

Hyperemia is one of the main reasons why patients with glaucoma do not adhere to or persist with their topical therapeutic regimen. Patients end up switching to another possibly more tolerable medication, and the changing of medications has significant financial implications. Latanoprost has the lowest incidence of hyperemia among the prostaglandin analogs. Patient adherence is crucial in a chronic progressive disease such as glaucoma, where non-adherence can lead to visual loss and decline in quality of life, creating societal health and economic burdens.

Glaucoma: Bimatoprost tolerability appears to be enhanced with switching strategy

The efficacy and tolerability of continuing latanoprost 0.005% (Xalatan, Pfizer) after 6 weeks of latanoprost monotherapy versus switching to bimatoprost 0.03% (Lumigan, Allergan) was investigated in an investigator-masked, randomized, parallel-group trial. The results showed good efficacy and tolerability in patients whose therapy was switched to bimatoprost and suggest that bimatoprost may be tolerated better after latanoprost pre-treatment.